Here are the DEF 14A proxy statements from Ultragenyx Pharmaceutical Inc. (RARE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RARE filings page.
Ultragenyx Pharmaceutical Inc. is asking stockholders to approve four key items at its virtual annual meeting on May 14, 2026. Investors will vote on re-electing three Class I directors, including founder and CEO Emil Kakkis, to serve until the 2029 meeting.
Stockholders are also asked to approve the Third Amended and Restated 2023 Incentive Plan, which adds 3.0 million shares and brings the plan’s share authorization to 14.5 million, extending it through May 14, 2036. The company reports a three-year average equity burn rate of 5.62% and an expected overhang of about 21% as of March 9, 2026.
Other proposals include ratifying Ernst & Young LLP as independent auditor for 2026 and an advisory say-on-pay vote on executive compensation, which emphasizes performance-based awards such as PSUs. The proxy highlights a largely independent, biopharma-experienced board and a range of governance practices, including a clawback policy, anti-hedging and anti-pledging rules, and director overboarding limits.